Another Reed Ethics Item

Writing on the The Niche stem cell blog for Nature magazine, Monya Baker also posted an item on the ethics case involving CIRM director John Reed. Baker's account can be found here.

Klein Ducks Little Hoover Questions

Late last year a California government efficiency agency investigating the state's $3 billion stem cell research effort asked its chairman, Robert Klein, what changes he would make in it after four years of experience.

Klein's response came in the form of what one might call a "modified stonewall." He will not answer the question because it would be "inappropriate" for him to give his views.

The matter involves the Little Hoover Commission, a state department charged with analyzing the performance of other state entities, and which has held one public hearing concerning CIRM. The commission's staffers and some of its members have also attended some CIRM meetings and interviewed other persons with an interest in the agency.

On Nov. 26, the Hoover commission sent a letter requesting Klein's views, a request first made at its hearing earlier that month. The letter asked for an answer by Dec. 15. On Dec. 19, Klein tried to rope in members of the CIRM board in fashioning a response, declaring that it would be "inappropriate" for him to respond, although he frequently says he wrote Prop. 71, the measure that created CIRM in 2004.

However, at least two board members balked. According to the transcript of the directors Legislative Subcommittee on Dec. 19, board member Jeff Sheehy, a communications manager at UC San Francisco, said,

"I would rather you just wrote the letter based on the items that you think are important."

Claire Pomeroy, dean of the UC Davis School of Medicine, told Klein,

"It's asking your opinion about writing the initiative, which was the process that happened before the board even existed. so it seems to me that it is appropriate for you to clarify your personal testimony in response to this letter."

Francisco Prieto, a Sacramento physician and CIRM board member, supported Klein's attempts to develop some sort of board consensus on changes.

During the meeting Klein indicated he would poll board members and perhaps staff about recommendations on possible changes.

Sheehy strongly objected to a detailed, full board review on the questions that the Little Hoover Commission directed to Klein. Sheehy warned that it could generate internal controversy that could have "negative consequences."

He said the board should focus on more important, unfinished work. Sheehy said,

"We're still working on trying to get a strategic plan for this institute....I can go down the list. We're still trying to get grants out. We're still trying to figure out a prescreening process. So there's a lot of the nitty-gritty stuff about our work we need to do."

On Dec. 22, Klein wrote a five-page letter to the Hoover Commission that said the "board is working well." He said the size of the board is beneficial because it provides diversity of viewpoints. He defended its conflict of interest rules, but did not mention the case of a director being investigated by the state for actions taken on the advice of Klein personally. He defended CIRM's transparency but did not discuss its perennial failure to provide timely public, Internet access to important background material on many proposals(including their texts) to be acted on at directors' meetings.

He also reiterated his refusal to give his personal opinion about changes. However, in the past he has publicly stated that the 50 person cap on staff was a mistake. He also has acknowledged attendance problems at board meetings, which often make it impossible to do business officially. Those problems stem from the structure of the board and its super-majority quorum requirements that are locked into state law. He also has supported triaging or prescreening grant applications because of difficulties with the grant review process.

We have asked CIRM for copies of the responses to Klein's queries concerning recommendations for changes. We will carry those when we receive them.

Reprogramming and Unicorns

CIRM President Alan Trounson has weighed in on some of the issues that attend the reprogramming of adult stem cells.

In a piece in the December 2008 issue of Cell Stem Cell entitled "Rats, Cats, and Elephants, but Still No Unicorn: Induced Pluripotent Stem Cells from New Species," Trounson noted that reprogramming is likely to attract attention from animal conservationists trying to preserve endangered species.

On the human front, he wrote,

"No matter how similar mouse, rat, and human iPSCs might be, it remains to beseen whether the usefulness of human iPSCs can be established, given the presence of viral sequences and of multiple copies of the transcription factors in potentially unregulated sites in the human genome. Regulatory agencies are likely to consider these lines to be genetically engineered and will consequently hold them to a very high bar in order to establish safety for use in human therapy. On the other hand, the potential availability of riPSCs for modeling human diseases will be very attractive to researchers and companies involved in drug discovery, as the mouse has often proven inadequate as a model for candidate therapeutics."

Chron on Reed Conflict Case

Reporter David Perlman of the San Francisco Chronicle on Wednesday wrote a piece on the ethics case involving a director of the California stem cell agency. Perlman secured a brief comment from the director, John Reed, who is also head of the Burnham Institute of La Jolla, Ca., Perlman wrote that Reed said only that he will now resume his activities on the CIRM board.

Reed Ethics Case Receives Modest Coverage

The ethics warning by California regulators involving a director of the state's $3 billion stem cell agency drew light news coverage today.

The conflict-of-interest incident received the most fulsome attention in two San Diego area newspapers, the Union-Tribune (Terri Somers writing) and the North County Times(Bradley Fikes writing). That's because the case involves John Reed, head of the Burnham Institute in La Jolla, Ca.

Erika Check, writing on the blog of Nature magazine, carried the following statement from Robert Klein, chairman of CIRM.

"We are delighted that with the completion of the review by the Fair Political Practices Commission. Dr. John Reed will reengage in his role as an ICOC [board] member. As CIRM matures, we continue to review and enhance our policies and procedures to avoid potential problems in the future."

It was Klein, an attorney who drafted much of Prop. 71, who advised Reed to write a letter lobbying the CIRM staff to reverse an unfavorable decision involving a $638,000 grant to Burnham. The letter prompted the state ethics investigation.

The Associated Press also wrote a brief story that appeared on various websites, including those of the San Francisco Chronicle, The Sacramento Bee and the San Jose Mercury News.

None of the stories carried a response from Reed, who Somers reported is traveling.

(An earlier version of this item did not contain the information from the Nature blog.)

Burnham's Reed Warned by State Ethics Agency on Conflict of Interest

California's government ethics overseers have issued a "warning letter" to a director of the California stem cell agency for attempting to influence the agency's staff to reverse a denial of a $638,000 grant to his research organization.

The attempt by John Reed, CEO of the Burnham Institute of La Jolla, Ca., was first disclosed by the California Stem Cell Report in November 2007.

Subsequently, John M. Simpson, stem cell project director for Consumer Watchdog of Santa Monica, Ca, asked the Fair Political Practices Commission to investigate Reed's action. California's top fiscal officer, Controller John Chiang, also called for an FPPC inquiry. Simpson disclosed the FPPC's warning today in a news release circulated nationally.

The FPPC said that Reed "intended to influence a decision that had the potential to affect his economic interests." The ethics agency said that Reed's action "raises ethical concerns," declaring,

"We are closing this matter with a warning letter....Dr. Reed is advised that failure to comply with the provisions of (state conflict of interest laws) can result in an enforcement action against him, including monetary penalties of up to $5,000 for each violation."

Reed recused himself from serving on the board during the FPPC investigation and appointed an alternate to fill in.

Simpson said he hoped that the 29 members of the CIRM board of directors had learned from the Reed incident. He said Reed can now return to the board and make a "positive contribution."

In response to an inquiry, Chiang's office said,

"Any conflict of interest threatens CIRM’s credibility and jeopardizes voters’ tremendous investment in stem cell research, which is why CIRM itself adopted a conflict-of-interest policy shortly after its creation.

"CIRM and the ICOC have a tremendous amount of work ahead of them – the controller hopes they can move forward and use the guidance provided by the FPPC to avoid any further conflicts in the grant process."

Simpson noted that the CIRM board is riddled with built-in conflicts of interest as the result of the language of Prop. 71, which created the $3 billion research effort.

Simpson said,

"Most of the people handing out the money are the very same people from the institutions that get the money. That means the conflict rules in place must be strictly adhered to and there must be consequences when they are violated.”

Reed wrote his letter seeking to influence the staff on the advice of CIRM Chairman Robert Klein, an attorney who wrote much of Prop. 71. Klein's action triggered calls for his resignation from The Sacramento Bee and Consumer Watchdog.

Ted Kennedy Backs Torres as CIRM Vice Chairman

Will the next vice chairman of the world's largest funding source for hESC research be Sen. Ted Kennedy's candidate or that of California Gov. Arnold Schwarzenegger?

John M. Simpson, stem cell project director for Consumer Watchdog of Santa Monica, Ca., disclosed Kennedy's endorsement of Art Torres, the head of the California Democratic Party, on the Consumer Watchdog blog last week.

Contesting Torres for the vice chairmanship of the $3 billion California Institute for Regenerative Medicine is Duane Roth, a current member of the CIRM board of directors, who was nominated by the Republican Schwarzenegger. Roth is also head of Connect, a San Diego area group supporting life science and technology businesses.

In a letter last month to CIRM Chairman Robert Klein, Kennedy said Torres is a friend of 37 years and declared that the former state lawmaker has an outstanding record of public service.

Torres' "years of advocacy for medical research and better health care for Californians will be a major asset" for CIRM, Kennedy said.

"A great deal is at stake," the Massachusetts Democrat said, "and I'm confident that Art Torres will make a difference for our country."

Simpson said he was not sure which candidate was best. Simpson wrote,

"The first task  for the ICOC (CIRM directors) is to define exactly what the vice chairman should be doing.  Both men need to offer a clear public statement of what he would bring to the position as well as his vision for the post." 

It is up to the 29-member CIRM board of directors to choose between Torres and Roth. No vote is yet scheduled.

CIRM's Financial Status, $500 Million Lending Program on the Table

Directors of the California stem cell agency next week will discuss how to run its ambitious and novel $500 million plan to lend money to the state's riskiest biotech ventures as well as the agency's own finances in the light of the Golden State's budget crisis.

The meeting of the Finance Subcommittee is scheduled for Jan. 21 at eight teleconference locations throughout the state. Businesses and others interested in the biotech loan effort should not miss the session.

Also on tap are plans to ask the Obama administration for loan guarantees that would, according to CIRM Chairman Robert Klein, enable CIRM to double its lending program to $1 billion.

No details are yet available on the agenda posted by CIRM on its web site.

Here is the information currently provided on the matters to be discussed:

"Consideration of policies and implementation plan/processes for CIRM loan program, including but not limited to the Loan Administration Policy and the role of delegated underwriters/financial service providers.

"Consideration of Stimulus Program topics

"Update on challenges of state finances and the impact on agency bond issues"

(Stimulus program topics are expected to include the loan guarantees.)

The loan program would target enterprises that cannot get normal financing because of their risk. Default rates are projected as high as 50 percent, but a $100 million "profit" is also expected. The excess is expected to be used for additional grants or loans.

Action taken at next week's meeting is likely to go before the full board of directors at its meeting on Jan. 29 in San Francisco.

The teleconference locations are in San Francisco(2), Menlo Park, La Jolla, Berkeley, Hillsborough, Irvine and Palo Alto. Specific addresses can be found on the agenda.

CIRM's $500 Million Loan Program: Lucrative Contract Looms

The California stem cell agency is seeking advice on its plan to have an outside contractor run a $500 million biotech lending program, and Friday is the deadline.

The information will play a key role in creating a potentially lucrative contract to administer the seven- to 10-year program for the $3 billion agency.

Banks, delegated underwriters and other financial service providers with an interest would be well-advised to weigh in with suggestions. The "request for information," however, is not limited to potential bidders but also solicits comments from "others with relevant experience or information."

CIRM is seeking information concerning the scope of services, models for relationships between "financial services providers/delegated underwriters" and CIRM, compensation structure and conflicts of interests.

CIRM is considering three possible models for the contractor:

"...a delegated underwriter model (delegated underwriter advances its own funds with CIRM guarantee), a hybrid model (delegated underwriter advances its own funds, but CIRM provides cash as collateral), and a fee for services model (CIRM originates loan and advances funds and pays financial services provider a fee for services)."

The stem cell agency states that its staff

"...does not have the internal expertise or capacity to manage all of the financial components of a loan program. CIRM therefore plans to externalize these tasks while maintaining ultimate control over the loan program. To ensure that CIRM obtains this expertise at the best value to California taxpayers, CIRM plans to issue a request for proposals to select two to three financial services providers/delegated underwriters. Because this is a start-up program, it is important to have at least two delegated underwriters at the outset. This would permit CIRM to learn from their different approaches and to refine our best practices. Furthermore, it would permit CIRM to transfer future transactions to another delegated underwriter if the relationship with one of the contractors is unsuccessful."

In February, CIRM plans to seek bids from potential contractors. The loan program is scheduled to begin this spring.

CIRM Begins Application Triage Experiment

The California stem cell agency is moving forward on its plan to perform closed-door, staff-connected triage on grant proposals before they move into the peer review process.

John M. Simpson, stem cell project director of Consumer Watchdog of Santa Monica, Ca., reported on the action by CIRM directors on Tuesday. But he suggests an alternative that could serve CIRM's desire to reduce the number of applications on some grant rounds. Just open up the grant application process so that the public would know who is applying and hear the pros and cons on the applications.

Writing on his organization's blog, he said,

"It's our $3 billion that's being handed out. If you want our money, you ought to be willing to ask for it in public. Nothing builds more trust in a review process than having it completely transparent."

Simpson reported that Tuesday's special, teleconference board meeting failed to muster a quorum despite an attempt to set up multiple out-of-state locations for the convenience of traveling board members. Only 15 checked in. Nineteen are needed for a quorum. The full board has 29 members.

Failure to attain a quorum meant no action on the request by the International Society of Stem Cell Research for $400,000 to help finance its $1.5 million convention in San Francisco in 2010. It was the second time the board has failed to act on the request.

Here is a link to CIRM's four-page explanation of the triage proposal. The process will be applied in the $60 million basic biology round. The RFA should be posted before the end of this year with the "pre-applications" due towards the end of January.

Correction

The Dec. 22, 2008, item on the ISSCR grant request from the California stem cell agency incorrectly gave the figure as $420,000 as the result of erroneous information from CIRM. The correct figure is $400,000. The additional $20,000 appeared in the CIRM grant application from the ISSCR which we have been told automatically adds 5 percent "indirect costs" to the amount requested. However, the 5 percent does not apply in this case.

Correction

The "financial status" item on Dec. 22, 2008, incorrectly said that CIRM stated that its grant money will run out at the end of this coming June. As noted later in the item, CIRM said it can "cover grant commitments at least through July 2009."

Attention Scientists: CIRM Proposes Triage on Research Plans

The California stem cell agency is proposing a form of scientific triage on research proposals, weeding them out even before they get into the peer review process.

Up for consideration at tomorrow afternoon's CIRM board meeting, the pilot project could have major implications for stem cell researchers in California, allowing them to bypass screening committees at their institutions. The proposal also would create another layer in the closed-door CIRM grant approval process, vest major, new authority with the CIRM staff and push the CIRM board even further away from the de facto decisions on grant applications.

The plan has yet to be published by CIRM on its web site. However, Don Gibbons, CIRM's chief communications officer, made an electronic copy of the Power Point presentation available to the California Stem Cell Report. If you would like a copy, please email the California Stem Cell Report (djensen@californiastemcellreport.com) or CIRM (info@cirm.ca.gov).

The proposal would involve a "pre-application review" of proposals that would involve CIRM staff and two members of the grants review group. It is patterned after "comparable procedures from from the Gates Foundation/MJFF/NIH/Genome Canada."

Some members of the CIRM board of directors balked at the proposal earlier this month. CIRM staff is bringing it up again tomorrow with changes aimed at addressing directors' concerns.

One key reason behind the proposal is to help ease the workload of the scientists who come from out-of-state to review applications. Sometimes the number of applications have run into the hundreds, creating time-consuming situations where scientists are reluctant to devote their time.

It is also designed to ferret out applications that are nixed by institutions prior to coming to CIRM. Marie Csete, CIRM's chief scientific officer, said the agency has received complaints that the best science is not always getting to CIRM.

She told directors earlier this month that CIRM may "not be seeing the full range of science from young scientists."

The public can participate in the meeting from locations in San Francisco (3), Berkeley, Elk Grove, Healdsburg, Los Angeles (3), Koloa, Hi., Beverly Hills, Irvine (2), La Jolla (2), Stanford, Cornelius, NC, Sacramento, Philadelphia and Chicago. The out-of-state locations are presumably where some CIRM directors will be tomorrow afternoon but they are still legally public as far as CIRM meetings go. The specific addresses can be found on the meeting agenda.

Stem Cell Science Group Seeks $400,000 From CIRM

Consumer Watchdog calls it "unbelievable" and "a flagrant squandering of public money." The group says it serves no purpose other "than to inflate the already healthy egos of CIRM's globe-trotting executives "

The language comes from John M. Simpson, stem cell project director for the Santa Monica, Ca., group. Writing on the group's blog, he refers to a pitch by the prestigious International Society for Stem Cell Research for $400,000 from CIRM to pay for 28 percent of the cost of the society's 2010 convention in San Francisco.

Tomorrow afternoon, the grant request will be considered by the CIRM board of directors at a special teleconference meeting. Multiple locations are available throughout the state and even outside of the state where the public can comment.

The request first came before the board earlier this month with no written explanation or detailed justification of benefits to the state of California. Directors told CIRM staff to provide more details if funding was to be seriously considered.

CIRM has close ties to ISSCR. CIRM President Alan Trounson is on the board of directors of the society. CIRM Chairman Robert Klein was a member of an advisory committee to ISCCR in 2007, according to The Niche, Nature magazine's stem cell blog. Don Gibbons, CIRM's chief communications officer, is a member of the group's public education committee.

The request for the grant is signed by Irv Weissman of Stanford, whose medical school dean is on the CIRM board of directors. Weissman will be president of the group in 2009. Stanford has received $95 million in grants from CIRM. Weissman has received $2.6 million.

It is not uncommon for professional organizations to seek some sort of financial assistance from enterprises whose executives serve on the professional group's board of directors.

However, the timing on this pitch is unfortunate, to say the least, given the $40 billion California budget shortfall. Moreover, funding of the convention seems a tad lavish. For example, it includes $235,000 for marketing expenses, a figure that seems more appropriate for MacWorld than a gathering of stem cell researchers.

Even in brighter times, a $400,000 donation from the state would be dubious. Today it cannot be justified unless CIRM wants to chalk up some serious minus points with the folks in the state Capitol and with the public at large.

The public can participate in the meeting from locations in San Francisco (3), Berkeley, Elk Grove, Healdsburg, Los Angeles (3), Koloa, Hi., Beverly Hills, Irvine (2), La Jolla (2), Stanford, Cornelius, NC, Sacramento, Philadelphia and Chicago. The out-of-state locations are presumably where some CIRM directors will be tomorrow afternoon but they are still legally public as far as CIRM meetings go. The specific addresses can be found on the meeting agenda.

(Editor's note: An earlier version of this item incorrectly stated that the ISSCR grant request totalled $420,000. The erroneous information came from CIRM. The additional $20,000 appeared in the CIRM grant application from the ISSCR which we have been told automatically adds 5 percent "indirect costs" to the amount requested. However, the 5 percent does not apply in this case. )

CIRM Clarifies Its Financial Status: Grant Money Could Run Out by June

How long can CIRM continue to operate at full strength given the current state of California's fiscal crisis?

According to CIRM, the agency can cover its "grant commitments" through the end of next July and perhaps longer. After that, the agency will have only enough money to monitor existing grants and perform other "office operations" for another 12 months.

The response came from Don Gibbons, chief communications officer for CIRM. We asked him to clarify apparent discrepancies in CIRM's financial status that were posed in the item below.

The matter is of some import since the state of California has suspended the issuance of state bonds because of the budget stalemate in Sacramento. Bonds constitute virtually the only source of funding for CIRM.

However, we think it is highly unlikely that bond sales will be suspended for the next six months. The state's budget problems should not be minimized, but a solution is almost certain to be found before June. If not, CIRM funding will be among the least of the worries in California.

More to the point is the fact that CIRM enjoys a favored financial position while the rest of state government is struggling. That situation poses PR and policy problems for CIRM that we have discussed previously.

For the record, here is Gibbons' response to questions about CIRM's financial status. They involved the $168.9 million CIRM budget figure in a San Francisco Business Times article and a $160 million figure given to us by Robert Klein, chairman of the stem cell agency. They also involved Gibbons' statement in the Times article that said CIRM had enough to fund office operations until July 2010. Gibbons replied:

"Both are correct. We have enough to cover grant commitments at least through July 2009, but will still have enough in reserve to fund 'office operations' for another year so that we can continue to monitor existing grants, manage the standards review processes, etc."

Gibbons did not respond to our question concerning CIRM's reaction to the governor's request for a 10 percent payroll reduction and mandatory furloughs that amount to a 9 percent salary cut.

(Editor's note: In an earlier version of this item, the second paragraph incorrectly reported that CIRM said its grant money would run out at the end of next June. The next to the last paragraph has also been rewritten to clarify that there were two elements in the question placed to Gibbons.)

Layoffs Loom at California State Agencies, Not Likely at CIRM

More details about the financial condition of the California stem cell agency are emerging as sweeping layoffs and pay cuts have been ordered at other state agencies.

On Friday, Gov. Arnold Schwarzenegger said 238,000 state employees must take what amounts to a 9 percent pay cut via mandatory, unpaid furloughs. He also ordered payroll cuts that amount to 10 percent, beginning Feb. 1.

The governor asked state agencies that he cannot directly control, such as the University of California and CIRM, to take similar action.

Also on Friday, Ron Leuty of the San Francisco Business Times reported:

"The California Institute for Regenerative Medicine next month will weigh a contingency financing plan that could include bond anticipation notes and a private placement with major philanthropic backers.

"The move, which would have to be approved by the state stem cell bond committee and Treasurer Bill Lockyer, comes against the backdrop of a financial markets meltdown that has clipped access to capital for companies and government agencies alike."

Leuty continued:

"CIRM has $168.9 million on hand, said spokesman Don Gibbons, and has enough to fund office operations until July 2010."

That statement is somewhat at variance with figures provided by California stem cell Chairman Robert Klein. He told the California Stem Cell Report earlier this month at the meeting of the CIRM board of directors at UC Irvine that $160 million was available between now and the end of June.

We are querying CIRM concerning the discrepancy and the governor's payroll cuts.

However, CIRM has been chronically understaffed since its inception and actually needs to hire more employees to bring it up to its legal cap of 50, which is tiny compared to the magnitude of running a program that has now awarded more than $600 million in building and research grants. The agency has already indicated it wants to add the much-needed employees, and, in our view, is not likely to roll back staffing levels

Leuty also had an interesting financial tidbit concerning Klein, who says that he has spent personally $6.5 million on behalf of Prop. 71 and CIRM.

Leuty wrote:

"Klein, who operates a financial advisory firm in Palo Alto, said he spent $5.5 million shepherding Proposition 71 through approval and has swallowed $1 million in CIRM-related costs since then while working 40-hour-plus workweeks as chairman."

CIRM Responds to Financial Disparity Questions

The California stem cell agency has responded to questions involving the cutbacks and issues raised in the "Handouts vs. Cutbacks" item below.

Don Gibbons, chief communications officer for CIRM, said Klein is not personally affected by the cuts in funding for affordable housing.

We also asked:

"Does CIRM have anything to say about whether it is appropriate for it to continue handing out tens of millions of dollars or more while facilities for the deaf go unfunded and cutbacks are made in levee reinforcement to protect Sacramento from becoming another Katrina-like disaster, among the thousands of other affected projects?"

Gibbons complete response, which are carrying word-for-word, was:

"The projects being frozen are funded through Pooled Money Investment accounts and CIRM has less than $2 million in that fund.  CIRM bonds have delayed repayment schedules, so have no impact at all on this year’s budget."

Handouts vs. Cutbacks: Strange Financial Tales from the Golden State

Citing the state's severe financial problems, California officials Wednesday shut down $3.8 billion in cash for public works projects, including some closely connected to directors of the state's stem cell agency. The action came coincidentally just one week after the agency gave away $20 million in state funds to stem cell researchers.

The cuts in bond-financed programs struck at projects to aid both the deaf and ailing veterans as well as to assist in genomics research. Also hit were construction projects at medical facilities at UC Davis and UC San Diego, both of which have representatives on the CIRM board.

Funding for hundreds, perhaps thousands, of housing projects was halted, raising the possibility that the moves could personally affect CIRM Chairman Bob Klein, whose real estate investment banking firm specializes in affordable housing.

CIRM spending, however, is a mere piffle compared to the state's $40 billion budget shortfall. But their financial disparity highlights the stem cell agency's unusual nature and the public policy issues that arise when ballot initiatives lock up state funds and create a favored place for some state programs.

The stem cell agency enjoys a relatively rosy position compared to nearly all other state departments. As the result of Prop. 71, which altered the state constitution and state law, CIRM is assured of state bond funding that goes directly to the agency and which cannot be touched by the governor or the legislature. In response to questions from CIRM directors last week, Klein said that the agency had enough money to operate normally at least until the end of June next year. Compare that to predictions that California will not be able to pay its bills by the end of February.

CIRM currently is drawing its cash primarily from the proceeds of a $250 million bond offering that was completed in the fall of 2007.

However, the state is not currently issuing any additional bonds because of the state's budget crisis, which includes $60 billion in debt and the worst credit rating of any state in the nation, according to the Wall Street Journal. Without additional funding, CIRM could run out of money at some point. However, Klein last week told the California Stem Cell Report that CIRM has $160 million to tide it over through the end of June. He also said he is working on a private placement plan for CIRM funding, just in case. Klein said he has already identified some potential participants although he did not spell out details.

Gov. Arnold Schwarzenegger and California lawmakers are wrestling with the budget crisis but have a long history of financial fumbling. At the heart of their failures is a daunting requirement that the legislature must pass a budget or increase taxes only with a two-thirds vote. That gives a minority extraordinary power. In California's case, Republican legislators stand in the way as they have for decades, chanting a mantra of no-new-taxes regardless of the state's needs.

Putting together solutions that will right the foundering Golden State will require compromise and policy changes that ultimately may affect such privileged endeavors as the state stem cell agency. Good arguments exist for steady funding of any sort of scientific research, much less stem cells. But good arguments also exist for steady funding of the state's now troubled institutions of higher learning, once an example for the nation, as well as many other laudable state programs.

CIRM must step carefully in the next few months to avoid becoming a symbol of what is wrong with much of California state government and its finances.

(Note: We have asked CIRM for comment on the issues raised by the disparity between its financial condition and that of the state. We have also asked whether Klein is affected by the housing cuts. We will carry CIRM's response when we receive it. Additionally, the San Francisco Chronicle carried a report this morning that the cutbacks would affect the "state's stem cell research center in San Francisco." No further details were provided, and we could not find anything to support that in the list of projects from the treasurer's office that we reviewed.)

'Armageddon' and Klein's Salary

The new salary for the chairman of the California stem cell agency, Robert Klein, has caught the attention of Nature magazine, which headlined its article on the subject: "Salary for CIRM head despite deficit, Outcry as stem cell agency puts chairman on payroll."

Erika Check Hayden wrote that CIRM directors approved the $150,000, halftime salary "even as the state plunges deeper into financial crisis." The term "financial Armageddon" also was quoted as coming from Gov. Arnold Schwarzenegger, who had expressed "deep concern" about the possibility of a salary prior to its approval last Wednesday by directors.

Nature magazine says it has 377,443 readers worldwide, mostly senior scientists and executives.

UCSF Snags $25 Million Stem Cell Donation

Despite the nation's financial woes, some philanthropists continue to pump out money with the latest coming from the Eli and Edythe Broad Foundation for the benefit of UC San Francisco's stem cell laboratory.

Broad, who made his fortune in home building and insurance, popped for $25 million on Wednesday. That brought his total for California stem cell research buildings to $75 million. He previously gave $20 million to UCLA and $30 million to USC.

Erin Allday of the San Francisco Chronicle wrote:

"The Broad Foundation donation, combined with a $35 million grant from the California Institute for Regenerative Medicine and a $16 million donation from Ray and Dagmar Dolby, means UCSF must raise another $47 million to complete funding for the new facility(see photo)."

Broad's contribution now brings him up to the level reached earlier this year by Lorry Lokey, founder of the Business Wire, who has funneled $75 million to Stanford for its stem cell work.

Gov. Arnold Schwarzenegger appeared for the UCSF announcement event along with CIRM Chairman Robert Klein. The donation garnered coverage throughout the state, including reports on television, which almost never covers the California stem cell agency. Google reported about 200 stories at different locations, including Taiwan and Australia. Most of those were the version from The Associated Press.

Richard Paddock of the Los Angeles Times wrote:

"Broad said that his foundation's investments have not suffered as much as other charitable foundations and that it would continue to meet its commitments.

"'I never thought I would say something like this, but we are blessed to be down less than 20%,' he said. 'So, we are going to keep on doing what we're doing and we'll look for better times.'"